Incyte (FRA:ICY) FCF Yield % : 3.87 (As of Apr. 27, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Incyte FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Incyte's Trailing 12-Month Free Cash Flow is €414 Mil, and Market Cap is €10,817 Mil. Therefore, Incyte's FCF Yield % for today is 3.87%.

The historical rank and industry rank for Incyte's FCF Yield % or its related term are showing as below:

FRA:ICY' s FCF Yield % Range Over the Past 10 Years
Min: -1.81 Med: 0.53 Max: 5.65
Current: 3.87

During the past 13 years, the highest FCF Yield % of Incyte was 5.65%. The lowest was -1.81%. And the median was 0.53%.

FRA:ICY's FCF Yield % is ranked better than
93.68% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs FRA:ICY: 3.87

Incyte's FCF Margin % for the quarter that ended in Dec. 2023 was 14.35%.

Incyte FCF Yield % Historical Data

The historical data trend for Incyte's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte FCF Yield % Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

3.34

-1.67

3.49

5.09

3.24

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															5.99	-3.42	8.72	4.14	4.20

Competitive Comparison of Incyte's FCF Yield %

For the Biotechnology subindustry, Incyte's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Incyte's FCF Yield % falls into.

Incyte FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Incyte's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	411.734	/	12703.61568
	=	3.24%

Incyte's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	133.388	*	4	/	12703.61568
	=	4.20%

Incyte FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Incyte FCF Yield % Related Terms

Thank you for viewing the detailed overview of Incyte's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (FRA:ICY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (FRA:ICY) Headlines

No Headlines